Providence Offers Multi-cancer Early Detection (MCED) Testing

What is Multi-cancer Early Detection (MCED)?

providence-genomics-saint-johns-galleri-multi-cancer-early-detection

Providence is offering Multi-cancer Early Detection (MCED) testing to empower providers and the public with a blood test that can identify many different types of cancer. Used alongside existing screening tools, MCED testing could improve early cancer detection for patients at an elevated risk of cancer, such as those 50 years and older. Providence is partnering with GRAIL to make their Galleri® MCED test available. Medical providers are encouraged to request a test kit for eligible patients.¹ See below.

Galleri® Multi-cancer Early Detection

  • Detects a shared cancer signal across 50+ types of cancer through a simple blood draw
  • Uses machine learning and methylation pattern recognition to detect a cancer signal
  • Predicts origin of the cancer signal to guide next steps to diagnosis

Detectable Cancers

  • Adrenal Cortical Carcinoma
  • Ampulla of Vater
  • Anus
  • Appendix, Carcinoma
  • Bile Ducts, Distal
  • Bile Ducts, Intrahepatic
  • Bile Ducts, Perihilar
  • Bladder, Urinary
  • Bone
  • Breast
  • Cervix
  • Colon and Rectum
  • Esophagus and Esophagogastric Junction
  • Gallbladder
  • Gastrointestinal Stromal Tumor
  • Gestational Trophoblastic Neoplasms
  • Kidney
  • Larynx
  • Leukemia
  • Liver
  • Lung
  • Lymphoma (Hodgkin and Non-Hodgkin)
  • Melanoma of the Skin
  • Merkel Cell Carcinoma
  • Mesothelioma, Malignant Pleural
  • Nasal Cavity and Paranasal Sinuses Nasopharynx
  • Neuroendocrine Tumors of the Appendix
  • Neuroendocrine Tumors of the Colon and Rectum
  • Neuroendocrine Tumors of the Pancreas
  • Oral Cavity
  • Oropharynx (HPV-Mediated, p16+)
  • Oropharynx (p16-) and Hypopharynx
  • Ovary, Fallopian Tube and Primary Peritoneum
  • Pancreas, exocrine
  • Penis
  • Plasma Cell Myeloma and Plasma Cell Disorders
  • Prostate
  • Small Intestine
  • Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs
  • Soft Tissue Sarcoma of the Head and Neck
  • Soft Tissue Sarcoma of the Retroperitoneum
  • Soft Tissue Sarcoma of the Trunk and Extremities
  • Soft Tissue Sarcoma Unusual Histologies and Sites
  • Stomach
  • Testis
  • Ureter, Renal Pelvis
  • Uterus, Carcinoma and Carcinosarcoma
  • Uterus, Sarcoma
  • Vagina
  • Vulva

“Providence is committed to collaborations that provide individuals with the best evidence-based care including advancements like early cancer screenings that can improve patient outcomes.”  

– Ora K. Gordon, M.D., Regional Medical Director of Providence’s Clinical Genetics & Genomics Program

Additional Information

 

¹ Recommend for use in adults with an elevated risk for cancer, such as those aged 50 or older. It should be used in addition to routine screening tests your healthcare provider recommends. The Galleri® test does not detect all cancers and not all cancers can be detected in the blood. False positives are false negatives results do occur.  The Galleri® test does not measure genetic risk of developing cancer in the future.